Cognition Therapeutics schedules FDA Type C meeting for Phase 3 endpoints

Cognition Therapeutics (CGTX) scheduled a Type C meeting with the FDA to align on endpoints for its Phase 3 trial of zervimesine (CT1812) in DLB.